LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

COVID-19 Saliva Testing Kits Can Also Measure Microscopic Organisms in the Mouth

By LabMedica International staff writers
Posted on 24 Nov 2021
Print article
Image: Illustration of rod-shaped and spherical (cocci) bacteria (Photo courtesy of Science Photo Library)
Image: Illustration of rod-shaped and spherical (cocci) bacteria (Photo courtesy of Science Photo Library)

COVID-19 saliva testing kits that include a novel preservative can also be used measure microscopic organisms in the mouth.

The finding by researchers at Rutgers University (New Brunswick, NJ, USA) enables study of the relationship between mouth and lung microbes and the SARS-CoV-2 virus that may allow for the development of new treatments. The study is the first to test the accuracy of these saliva-based, at-home COVID test kits in measuring the oral microbiome, the bacteria found in animals and humans.

Salvia tests use preservatives to maintain genetic material (RNA) in the SARS-CoV-2 virus to enable fast results. However, until now, it was unknown if it also would preserve the bacterial genetic material. To test the ability to measure the microbiome in the saliva COVID test kits, the researchers collected saliva samples from 22 participants with the kits and in empty tubes. Six of the participants also came back the next days to give another set of samples so the researchers could study their microbiome over time. They then compared their ability to measure the microbiome in both types of saliva collection.

They found that the samples collected in the COVID testing kits still allowed for accurate measuring of the bacteria and gave a more stable picture of the microbiome over time compared to samples collected in kits without a preservative. These findings mean that saliva collected for COVID testing can also be used to measure microbes in the mouth and help further our understanding of the systemic effects of COVID infection and also help researchers to develop probiotic- or microbiome-centered therapies to help treat COVID-19.

“We inhale a small amount of our saliva every day, so it makes sense that some of the microbes that live in our mouths would end up in our lungs,” said lead author Abigail Armstrong, a postdoctoral fellow at the Center for Advanced Biotechnology and Medicine (CABM) at Rutgers. “By studying the mouth microbiome in these banked samples of people with or without COVID-19, we can get an idea of how the microbial environment in the mouth and lung might impact the disease.”

Related Links:
Rutgers University 

Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Multi-Function Pipetting Platform
apricot PP5
New
Immunofluorescence Analyzer
MPQuanti

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.